Area Business Lead - Hospital, Anti-Infectives
About the job
- A bachelor's degree is required; an MBA or master's degree is preferred.
- At least 10 years of successful pharmaceutical-industry sales or management experience is required; anti-infective experience is highly preferred.
- Previous experience as a hospital pharmaceutical district manager is preferred.
- Prior experience as either a people manager or a peer leader who mentors and coaches others, plus a consistent high-performance record within a hospital pharmaceutical sales team, is required.
- Strong understanding of how hospital products are purchased, ordered, and administered, including the formulary process and reimbursement policies.
- Ability to understand and navigate hospital and institutional systems to gain access to key decision makers.
- Experience building rapport and relationships in institutional settings to expand product awareness and utilization and make an immediate impact on healthcare professionals.
- Ability to communicate clinical data.
- Business-to-business experience and/or ability to demonstrate strong influencing skills.
- Excellent oral, written, and presentation communication skills, and human resources skills.
- Demonstrated business acumen, selling, leadership, and coaching, training, and development abilities.
- Strong initiative, judgment, and decision-making ability.
- Ability to strategically plan, organize, and adapt.
- Must complete the full onboarding curriculum and pass live-call certification and mock objections during ride-along training.
- Valid driver's license with a clean driving record; ability to pass a complete background check and meet the company's Fleet/Car Allowance Policy standards.
- Must have valid licenses and credentialing required to conduct business in the assigned territory.
- Significant field travel (approximately 80%), which can include overnight and/or weekend travel.
- Must attend refresher meetings on product and disease-state updates.
- Ability to drive or fly to target accounts, customers, meetings, and conventions.
- Ability to articulate clearly and conduct verbal presentations with large and small audiences.
- Ability to travel by automobile and/or airplane.
- Ability to view video display terminal images less than 18 inches away for extended periods, up to four hours at a time.
- Ability to operate a computer keyboard and telephone.
- Ability to sit for extended periods, up to four hours at a time.
- Ability to lift, tug, and pull up to 15 pounds.
- Create and implement a Key Account Management strategy, aligning and executing territory account plans across each Key Account Manager's geography to achieve monthly, quarterly, and annual product-access and launch objectives.
- Recruit, hire, train, and retain a diverse, high-performing team of hospital Key Account Managers and develop them to their full potential.
- Develop a pool of Key Account Manager talent to potentially fill future vacancies.
- Identify Key Account Manager performance challenges or deficiencies early and create plans to address performance gaps; partner with management and Human Resources to guide disciplinary action.
- Develop Key Account Managers by observing their business acumen, customer interactions, and work with internal matrix teams, and provide individual coaching, feedback, and support for success in their current and future roles.
- Act as a player-coach with Key Account Managers in priority accounts to communicate assigned product clinical data strategically and accurately to executive-level stakeholders and key opinion leaders.
- Provide regular, candid, and timely feedback on communication, account management skills, and performance, documenting it in field coaching reports and mid-year and year-end reviews for each team member.
- Develop and execute business plans to achieve regional and national goals; analyze and evaluate each Key Account Manager territory's performance; and use appropriate data sources to develop tactical plans.
- Set and maintain team standards for product knowledge, activity, and account management skills.
- Maintain knowledge of assigned products, treatment regimens, competitor products, and market and industry trends, and teach and coach Key Account Managers on this information.
- Plan and conduct Key Account Manager team meetings to implement company objectives and strategies.
- Conduct consistent field coaching days with each Key Account Manager.
- Develop and maintain effective working relationships with key strategic accounts and regional stakeholders.
- Communicate candidly and promptly with management, Regional Account Managers, brand leadership, and internal and external stakeholders.
- Model compliance with company policies, expectations, and required regulations.
- Maintain performance management documents in accordance with company standards.
- Manage the team's budget and resources; maintain complete records and submit reports as directed by management.
- Adjust work style or approach to fit the situation and dedicate time and energy to self-development.
- Identify and meet internal and external customer needs by building relationships and delivering solutions.
- Develop mutually beneficial relationships with Regional Account Managers to meet and exceed company access goals.
- Achieve access goals while following ethical business practices and required regulations.
- Drive safely to required meetings and appointments.
- Anti-infective experience is highly preferred.
- Previous experience as a hospital pharmaceutical district manager is preferred.
- An MBA or master's degree is preferred.
About the company
Shionogi expanded its U.S. portfolio by acquiring Victory Pharma’s marketed products, focusing on pain management and anti-infectives. Victory Pharma developed and marketed prescriptions such as Naprelan (a controlled-release naproxen) and anti-infectives like MOXATAG and KEFLEX for pain, rheumatology, and infectious diseases. Shionogi uses its existing U.S. sales force to market these FDA-approved products to doctors, quickly establishing a market presence. The strategy aims to grow in the United States by integrating Victory Pharma’s products into Shionogi’s sales and marketing reach, though Victory Pharma later faced a federal settlement related to promotional practices.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Florham Park, New Jersey
Founded
2001
Get referred to Shionogi
See people who can refer or advise you
Simplify's Take
What believers are saying
- SCORPIO-PEP cut symptomatic COVID-19 by 67%, creating immediate U.S. launch momentum.
- Radicava adds roughly $700 million annual sales, immediately accretive in fiscal 2026.
- February 13, 2026 reorganization and April 1, 2027 Torii merger tighten operations.
What critics are saying
- XOCOVA depends on transient exposure-driven demand; sales fade as COVID waves normalize.
- Radicava's $2.5 billion price amplifies concentration risk if ALS uptake stalls.
- Shionogi's 2026 growth rests on two launches; one miss leaves earnings entirely Japan-bound.
What makes Shionogi unique
- Shionogi controls XOCOVA, FDA-approved June 1, 2026, first oral COVID-19 post-exposure prophylaxis.
- April 2, 2026 Radicava acquisition gave Shionogi global ALS rights and commercial infrastructure.
- Shionogi pairs infectious-disease depth with Japan-U.S. manufacturing and regulatory execution.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
401(k) Retirement Plan
401(k) Company Match
Growth & Insights and Company News
6 month growth
10%1 year growth
10%2 year growth
10%Shionogi to acquire IntraBio for $2.0bn. October 5, 2026 at 06:10 AM UTC - By FilingReader AI Shionogi & Co., Ltd. has announced an agreement for its U.S. subsidiary to acquire IntraBio Inc. as a wholly owned subsidiary for an upfront consideration of $2.0bn, with the transaction scheduled between November and December 2026. The transaction adds IntraBio's rare disease portfolio, highlighted by AQNEURSA, to Shionogi's growing capabilities in rare neurodegenerative and genetic neurological diseases. AQNEURSA is approved in the U.S. and EU for Niemann-Pick disease type C and recently received FDA approval for treating Ataxia-Telangiectasia. Additionally, the acquisition brings clinical programs targeting Pompe disease, Fragile X syndrome, and Jordan's syndrome into the company's pipeline. This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact [email protected] TSE:4507 - Tokyo Stock Exchange Get instant email alerts when Shionogi & publishes news Free account required - Unsubscribe anytime Filing activity timeline. October 4, 2026 This News Filings (90 days): 14 documents Most recent: Oct 4
Shionogi to showcase advancements across its infectious disease portfolio at IDWeek 2026. Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C. Data highlights at IDWeek 2026 include an oral presentation featuring a subpopulation analysis from the global Phase 3 SCORPIO-PEP trial, a rapid-fire session focused on ventilator-associated pneumonia isolates from the SENTRY Antimicrobial Surveillance Program and 18 additional presentations across Shionogi's COVID-19 antiviral and Gram-negative antibiotic programs.
Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) short interest update. August 29, 2026 Key points. * Short interest fell 49.6% to 3,812 shares as of August 14, representing effectively 0.0% of shares outstanding and a 0.0-day short-interest ratio. * Shionogi reported quarterly EPS of $0.36, beating estimates of $0.18, while revenue of $1.04 billion exceeded the $970.69 million consensus forecast. * Analyst sentiment improved, with Jefferies and Goldman Sachs upgrading the ADR to "strong buy"; MarketBeat lists an overall average rating of "Buy." * MarketBeat previews top five stocks to own in September. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 3,812 shares, a decline of 49.6% from the July 30th total of 7,564 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 150,205 shares, the short-interest ratio is currently 0.0 days. Shionogi & Co., Ltd. Unsponsored ADR stock down 0.6%. Shares of SGIOY stock opened at $9.04 on Friday. Shionogi & Co., Ltd. Unsponsored ADR has a one year low of $7.65 and a one year high of $12.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock has a fifty day moving average price of $8.85 and a 200 day moving average price of $9.76. The stock has a market cap of $15.39 billion, a P/E ratio of 9.04, a price-to-earnings-growth ratio of 3.36 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.47%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $970.69 million. Analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current year. Institutional inflows and outflows. An institutional investor recently bought a new stake in Shionogi & Co., Ltd. Unsponsored ADR stock. Birmingham Capital Management Co. Inc. AL purchased a new position in shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,950 shares of the company's stock, valued at approximately $257,000. Hedge funds and other institutional investors own 1.92% of the company's stock. Analysts set new price targets. Several research firms recently commented on SGIOY. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 14th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "strong sell" rating to a "hold" rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy". Discover more Options Profit Calculator AI Infrastructure Stocks Stock Split Calculator Shionogi & Co., Ltd. Unsponsored ADR company profile. Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders. The company's product portfolio spans both established and innovative therapies. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Shionogi & Co., Ltd. Unsponsored ADR, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shionogi & Co., Ltd. Unsponsored ADR wasn't on the list. While Shionogi & Co., Ltd. Unsponsored ADR currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
StreetAccount summary - asian market recap: Nikkei +3.66%, Hang Seng +0.24%, Shanghai Composite +1.47% as of 04:10 ET. Aug 05 ,2026 * Synopsis: * Asia equities rallied almost everywhere for a second consecutive day Wednesday. Technology-leaning benchmarks in South Korea, Taiwan and Japan saw the sharpest gains, while Shenzhen outperformed in mainland China. Hong Kong and Shanghai saw more modest gains while Australia's ASX reached a fresh record high. India has pared early gains while Southeast Asia is mixed. US futures higher, Europe opened with modest gains. US dollar unchanged, NZD slipped after strong jobs data, yuan and yen flat. Treasuries mixed, JGB yields lower, IGBs unchanged following RBI decision. Precious metals rallying with gold at a two-month high. Crude futures seeing more declines as Brent falls below $79/bl. Base metals higher again. Cryptocurrencies mixed. * Asia equities rallied further Wednesday following the overnight surge on Wall Street that took the S&P 500 to a fresh record high, and as futures indicate another strong open this morning in the US. SpaceX's after-hours share price decline unlikely to dissuade the bulls who received support overnight from Treasury Secretary Bessent who said a deal with Iran was imminent and an Axios report that said the US, Iran and Oman would announce an agreement to reopen the Strait of Hormuz later today. Asia equities received a further boost as the dollar remained at six-week lows, boosting local currencies and providing an additional tailwind. * In other developments, China's RatingDog Services PMI declined by more than expected and service growth in Japan also slowed; Singapore full PMI expanded further as new orders and output expanded further. Japan real wages rose for a sixth consecutive month. India's central bank kept its repo rate steady, raised its FY GDP growth forecast and lowered inflation projections but warned over risks to both forecasts from weather and geopolitical developments. * Zhongji Innolight (3308.HK) shares under pressure on a report saying the US was drafting a ban on the import of China-made optical receivers. Shein (+SHEIN) is targeting a $30-40B valuation in its Hong Kong IPO later this month, sources told Reuters. CXMT (688825.CH) is set to produce smartphone memory chips on par with industry's best, according to sources cited by Bloomberg. Shionogi's (4507.JP) CEO said the company is actively pursuing at least three acquisitions, and is considering an expansion in the US. Wistron (3231.TT) says AI server demand remains strong as quarterly profits more than double. Coupang (CPNG) posted a net quarterly loss following fines connected to its massive data breach last November. Samsung Electronics (005930.KS) and SK Hynix (000660.KS) are testing China-made chip tools as hedge against US risk, according to a Reuters report. * Digest: * Notable Gainers: * +24.5% 4062.JP (IBIDEN): reports Q1 results; revenue and operating profit beat FactSet estimates; raises FY guidance * +8.1% 669.HK (Techtronic Industries): reports H1 results * +5.0% 3034.TT (Novatek Microelectronics): reports Q2 EPS NT$10.40 vs FactSet NT$7.93 * +4.7% 9434.JP (SoftBank Corp): reports Q1 results; revenue and operating profit beat StreetAccount estimates * +4.0% 5401.JP (NIPPON STEEL): reports Q1 results; revenue and business profit beat FactSet estimates * +3.8% 196170.KS (Alteogen): signs exclusive license agreement for ALT-B4 * +1.8% 017670.KS (SK Telecom): reports Q2 results; operating profit beats StreetAccount estimates * Notable Decliners: * -6.8% 293490.KS (Kakao Games): reports Q2 results; revenue misses FactSet estimates * -6.3% 6367.JP (DAIKIN INDUSTRIES): reports Q1 results; net income misses FactSet estimates * -5.1% 4980.JP (Dexerials): reports Q1 results; revenue below FactSet estimates * -3.4% 3064.JP (MonotaRO): reports H1 results * Data: * Economic: * China July * July RatingDog Services PMI 50.4 vs consensus 53.7 and 54.1 in prior month * Composite PMI 50.8 vs 53.6 in prior month * India July * Final services PMI 53.3 vs flash 53.1 and 57.4 in prior month * Composite PMI 54.3 vs flash 54.3 and 57.1 in prior month * Japan * June average nominal wages +3.4% y/y vs consensus +3.4% and revised +3.3% in prior month * Real wages +1.6% y/y vs consensus +1.6% and revised +1.6% in prior month * July final services PMI 51.2 vs flash 51.9 and 52.2 in prior month * Composite PMI 52.7 vs flash 53.1 and 52.8 in prior month * New Zealand Q2 * Employment +0.5% q/q vs consensus +0.1% and revised +0.1% in Q1 * Unemployment rate 5.6% vs consensus 5.4% and 5.3% in Q1 * Singapore June * Retail sales y/y +4% versus +2.9% in prior month * Markets: * Nikkei: 2,342.91 or +3.66% to 66300.44 * Hang Seng: 62.90 or +0.24% to 25915.82 * Shanghai Composite: 56.15 or +1.47% to 3878.43 * Shenzhen Composite: 51.45 or +2.07% to 2537.55 * ASX200: 82.00 or +0.90% to 9227.80 * KOSPI: 239.31 or +3.76% to 6598.26 * SENSEX: (19.38) or (0.02%) to 78409.57 * Currencies: * $-¥: +0.01 or +0.01% to 157.7490 * $-KRW: (4.12) or (0.29%) to 1425.6000 * A$-$: +0.00 or +0.01% to 0.7046 * $-INR: (0.01) or (0.01%) to 95.1646 * $-CNY: (0.00) or (0.07%) to 6.7485
Shionogi launches XOCOVA in the U.S. for prevention of COVID-19 following exposure. Wednesday, July 29, 2026 Shionogi has announced the U.S. availability of XOCOVA(R)(ensitrelvir), the first and only oral antiviral approved to help prevent COVID-19 after exposure. The treatment is indicated for adults and adolescents aged 12 years and older who have been in contact with someone infected with COVID-19 and is now available through the company's U.S. subsidiary, Shionogi Inc. XOCOVA works by blocking viral replication during the period between exposure to the virus and the onset of symptoms. The treatment is taken once daily for five days, beginning with a loading dose of 375 mg on the first day, followed by 125 mg once daily on days two to five. It should be started as soon as possible and within 72 hours of exposure to an infected individual. The launch comes as health authorities continue to monitor seasonal increases in COVID-19 cases in the United States. The company highlighted that post-exposure prophylaxis is an established approach used for other infectious diseases and may help reduce the burden of COVID-19 by preventing infection after exposure. Shionogi is supporting the commercial rollout of XOCOVA through healthcare professional and public education programmes, alongside partnerships with national and regional pharmacy networks to improve product availability across the United States. The company is also offering a co-pay assistance programme for eligible commercially insured patients to help reduce out-of-pocket costs. For the U.S. market, all stages of XOCOVA manufacturing, including active pharmaceutical ingredient production, drug formulation, packaging, quality control, release testing, supply chain management and distribution, are carried out within the United States.